Published in Int J Cancer on March 02, 2016
The role of miR-24 as a race related genetic factor in prostate cancer. Oncotarget (2017) 0.75
Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. BMC Cancer (2017) 0.75
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys (2006) 11.17
Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst (2011) 10.29
Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res (2008) 3.39
Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer (2004) 2.22
Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol (2007) 2.09
Population-specificity of human DNA methylation. Genome Biol (2012) 2.04
Racial differences in gene-specific DNA methylation levels are present at birth. Birth Defects Res A Clin Mol Teratol (2011) 1.88
Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer (2005) 1.87
Evidence for field cancerization of the prostate. Prostate (2009) 1.86
Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology (2003) 1.84
Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst (2006) 1.70
Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest (2009) 1.64
DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med (2013) 1.63
Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res (2011) 1.63
Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. J Urol (2012) 1.60
Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol (2009) 1.58
Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes. Cancer Biol Ther (2009) 1.55
Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int (2001) 1.52
Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate (2008) 1.46
Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res (2010) 1.38
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer (2013) 1.37
Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol Biomarkers Prev (2013) 1.32
Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res (2005) 1.30
High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res (2007) 1.30
CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology (2008) 1.24
Association between cancer-free survival and telomere DNA content in prostate tumors. J Urol (2005) 1.21
Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. Exp Cell Res (2012) 1.17
GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer. J Urol (2014) 1.12
A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett (2004) 1.12
Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv Anat Pathol (2008) 1.11
Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res (2010) 1.09
Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol Biomarkers Prev (2009) 1.07
Genome abnormalities precede prostate cancer and predict clinical relapse. Am J Pathol (2012) 1.03
Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer. Mod Pathol (2012) 1.01
Genome-wide methylation analysis of prostate tissues reveals global methylation patterns of prostate cancer. Am J Pathol (2013) 1.00
Markers of field cancerization: proposed clinical applications in prostate biopsies. Prostate Cancer (2012) 1.00
High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome. Mol Med (2009) 0.98
CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics (2006) 0.96
Gene promoter methylation and its potential relevance in early prostate cancer diagnosis. Pathobiology (2010) 0.91
A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis. Prostate (2014) 0.91
Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer. PLoS One (2013) 0.90
Strategies for repeat prostate biopsies. Curr Urol Rep (2009) 0.89
Pathogenic intestinal bacteria enhance prostate cancer development via systemic activation of immune cells in mice. PLoS One (2013) 0.86
Methylation of the RARB gene increases prostate cancer risk in black Americans. J Urol (2013) 0.86
DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer. Anticancer Res (2013) 0.85
Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev (2014) 0.85
DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer. PLoS One (2015) 0.79
Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens. Prostate (1997) 0.79